CLOUD
CLOUD
CLOUD
Oracle to help US government test malaria drugs for coronavirus treatment
Oracle Corp. is lending its expertise to help the U.S. government run clinical trials on two malaria drugs to gauge their effectiveness in treating COVID-19, the respiratory disease caused by the coronavirus.
The New York Times said Oracle was currently in talks with the White House about providing a “platform” for the testing.
Officials are still working out the details, but the plans seems to be that the Department of Health and Human Services, Food and Drug Administration and Centers for Medicare and Medicaid will use it to analyze how the drugs perform when administered to COVID-19 patients.
U.S. President Donald Trump has been enthusiastic about the potential of the malaria drugs chloroquine and hydroxychloroquine in treating the disease. There has been some anecdotal evidence that the drugs can help to reduce the severity of symptoms, but more testing is required before any official treatment can be sanctioned.
Oracle’s platform would reportedly be used to track treatments, store information on their effectiveness and collect any additional data that might be useful for researchers.
The New York Times said the data would be critical for researchers trying to determine the effectiveness of chloroquine and hydroxychloroquine. The drugs have already been used on some patients, but only on a largely “uncontrolled basis,” the report added.
Photo: Leo2014/Pixabay
A message from John Furrier, co-founder of SiliconANGLE:
Support our mission to keep content open and free by engaging with theCUBE community. Join theCUBE’s Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities.
- 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more
- 11.4k+ theCUBE alumni — Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network.
About SiliconANGLE Media
SiliconANGLE Media is a recognized leader in digital media innovation, uniting breakthrough technology, strategic insights and real-time audience engagement. As the parent company of SiliconANGLE, theCUBE Network, theCUBE Research, CUBE365, theCUBE AI and theCUBE SuperStudios — with flagship locations in Silicon Valley and the New York Stock Exchange — SiliconANGLE Media operates at the intersection of media, technology and AI.
Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Our new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.
